Business
HEALWELL AI Reaches 47 Peer-Reviewed Publications, Strengthening Its Scientific Moat for AI-Powered Real-World Clinical Evidence Generation
HEALWELL achieves its 47 th total peer-reviewed publication validating its DARWEN™ AI acr...
About this update from Healwell Ai Inc. Class A
[{"type":"text","content":"HEALWELL AI Reaches 47 Peer-Reviewed Publications, Strengthening Its Scientific Moat for AI-Powered Real-World Clinical Evidence GenerationHEALWELL achieves its 47th total peer-reviewed publication validating its DARWEN™ AI across multiple disease areas and diverse patient populations.HEALWELL presented new scientific validation of DARWEN™ AI at the European Crohn's and Colitis Organisation (ECCO) meeting, with findings published in the Journal of Crohn's and Colitis(1).The study conducted with the U.S. affiliate of a large pharmaceutical partner, demonstrated how AI-enriched Canadian patient support program data can generate real-world evidence to support U.S. Medical Affairs and market access initiatives.HEALWELL has secured three additional conference acceptances in 2026 in collaboration with leading global life sciences companies across diabetes, dermatology and inflammatory bowel disease (IBD) research.Toronto, Ontario--(Newsfile Corp. - March 12, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) (\"HEALWELL\" or the \"Company\"), a healthcare artificial intelligence company focused on preventative care, today announced continued scientific validation of its DARWEN™ AI platform, with new research accepted for presentation at major international scientific conferences, including the European Crohn's and Colitis Organisation (ECCO) meeting, with publication in the Journal of Crohn's and Colitis(1). The study, conducted with the U.S. affiliate of a large pharmaceutical partner, demonstrated how AI-enriched Canadian patient support program data can generate real-world evidence to support U.S. Medical Affairs and market access initiatives, creating significant new commercial opportunities with existing pharmaceutical customers.These new acceptances bring the total number of peer-reviewed publications validating DARWEN™ AI to 47, spanning multiple disease areas and diverse patient populations.In 2026, HEALWELL has already secured three additional conference acceptances in collaboration with leading global life sciences companies, highlighting the growing adoption of DARWEN™ AI in real-world clinical research and evidence generation. The new clinical research studies examine:Treatment patterns of patients with inflammatory bowel diseaseAI-enabled clinical decision support to improve T...